850101P

13:0 Lyso PI

1-tridecanoyl-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol) (ammonium salt), powder

• Synonym(e): PI(13:0/0:0); 110716
• Empirische Formel (Hill-System): C₂₂H₄₆NO₁₂P
• CAS-Nummer: 1246430-02-3
• Molekulargewicht: 547.57
• UNSPSC-Code: 51191904
• NACRES: NA.25

Eigenschaften

• Assay: >99% (LPI; may contain up to 10% of the 2-LPI isomer, TLC)
• Form: powder
• Verpackung: pkg of 1 × 100 μg (with stopper and crimp cap (850101P-100ug)); pkg of 1 × 500 μg (with stopper and crimp cap (850101P-500ug))
• Hersteller/Markenname: Avanti Research^™ - A Croda Brand 850101P
• Lipid-Typ: phospholipids; cardiolipins
• Versandbedingung: dry ice
• Lagertemp.: −20°C
• SMILES String: [H][C@@](COP([O-])(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O)=O)(O)COC(CCCCCCCCCCCC)=O.[NH4+]

Beschreibung

Allgemeine Beschreibung

Lysophosphatidylinositol (LPI), produced by phospholipase A2 is a bioactive lipid.

Anwendung

13:0 Lyso PI (1-tridecanoyl-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol) may be used as a nonendogenous phospholipid (PL) standard for the quantitative analysis of PLs. It may also be used as a standard for tandem mass spectrometry analysis of lipid species in human plasma.

Biochem./physiol. Wirkung

Increased circulating levels of L-alpha-lysophosphatidylinositol (LPI) are associated with cancer and LPI is a potent ligand for the G-protein-coupled receptor GPR55.

Lysophosphatidylinositol (LPI) is expected to play a vital role in various diseases. Ca²⁺ channels at the plasma membrane and mitochondrial membrane are controlled by LPI. It can also stimulate various signaling pathways to control several cellular processes. LPI can block the migration of cells.

Verpackung

2 mL Amber Serum Vial with Stopper and Crimp Cap (850101P-100ug)

2 mL Amber Serum Vial with Stopper and Crimp Cap (850101P-500ug)

Rechtliche Hinweise

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids